Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Inovio Pharmaceuticals, Inc./ 10-Q

Quarterly Report · 10-Q

Inovio Pharmaceuticals, Inc.

INONASDAQEQUITYCurrent

Quarterly Report

Filed Aug 12, 2026Accepted Aug 12, 2026, 4:00 PM EDTCIK 1055726Accession 0001055726-26-000023
View company →Permanent SEC source ↗
Share

Company context

INOVIO’s DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO’s proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body’s cells can download to produce specific proteins to target and fight disease. INOVIO’s proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body’s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.

Current securities

INONASDAQ · EQUITY · Current

Recent company filings

  1. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 6, 2026
  2. Results of Operations and Financial ConditionAug 12, 2026
  3. SCHEDULE 13G/A - filed by Adage Capital Management, L.P. regarding INOVIO PHARMACEUTICALS, INC.Aug 12, 2026
  4. SCHEDULE 13G - filed by RA CAPITAL MANAGEMENT, L.P. regarding INOVIO PHARMACEUTICALS, INC.Aug 7, 2026
  5. SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding INOVIO PHARMACEUTICALS, INC.Jul 31, 2026

Registered securities in this filing

INOVIO PHARMACEUTICALS, INC. · 10-Q · Filed 2026-08-12

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

COMMON STOCK, $0.001 PAR VALUE

Symbol
INO
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000105572626000023 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.